Clinical Efficacy of Combination Chemotherapy with Ifosfamide Cisplatin, and Etoposide(ICE) in Advanced Non-Small Cell Lung Cancer.
10.4046/trd.2002.52.4.309
- Author:
Gu LEE
1
;
Byung Duk KIM
;
Hee Jung KANG
;
Sang Won LEE
;
Hyun A OH
;
Sung Hwa BAE
;
Jae Lyun LEE
;
Kyung Hee LEE
;
Myung Soo HYUN
;
Kyeong Cheol SHIN
;
Jin Hong JUNG
;
Kwan Ho LEE
;
Hun Mo RYU
Author Information
1. Department of Internal Medicine, College of Medicine, Yeungnam University, Korea. impride@dreamwiz.com
- Publication Type:Original Article
- Keywords:
Ifosfamide;
Cisplatin;
Etoposide;
g Non-small-cell lung cancer;
Chemotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Cisplatin*;
Drug Therapy;
Drug Therapy, Combination*;
Etoposide;
Febrile Neutropenia;
Humans;
Ifosfamide*;
Leukopenia;
Lung;
Mesna
- From:Tuberculosis and Respiratory Diseases
2002;52(4):309-316
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: To evaluate the efficacy and toxicity of combination chemotherapy using ifosfamide, cisplatin, and etoposide in patients with advanced non-small cell lung cancer(NSCLC). MATERIALS AND METHODS: Thirty-three patients with inoperable NSCLC(stage III b+IV) who had measurable diseases, and had not been treated with chemotherapeutic drugs, were enrolled in this study(from March 1995 to December 1996). The patients received ifosfamide(1500mg/m2/day, a full drop with Mesna on days 1-5), Cisplatin (80mg/m2/day infusion with a hydration on day 2), and Etoposide (100mg/m2/day infusion for 2 hours on days 1-3). The treatment was repeated every 4 weeks. RESULTS: Ten patients showed a partial responses (30.3%). The overall survival time of the responders was longer than that of the non-responders (median 55 vs 22 weeks, p=0.01). The toxicities of this treatment were tolerable. Grade 3 or 4 leukopenia was observed in 21%. There was 1 death related to febrile neutropenia. The non-hematologic toxicity was mild. The relative dose intensity given to the patients was 0.86 ifosfamide, 0.87 cisplatin, and 0.89 etoposide, showing an average dose intensity of 0.87. CONCLUSIONS: A combination regimen of ifosfamide, cisplatin, and etoposide is effective and tolerable for treating advanced non-small cell lung cancer.
